Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.91 USD

1.91
684,092

+0.14 (7.91%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1.92 +0.01 (0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Accuray's (ARAY) Radiotherapy Technologies Adopted by Unicancer

by Zacks Equity Research

Accuray's (ARAY) proprietary radiotherapy technologies get selected by Unicancer, which is the largest network of comprehensive cancer centers in Europe.

Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment

by Zacks Equity Research

Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.

Why Is Accuray (ARAY) Down 3.4% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues

by Zacks Equity Research

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.

Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 0.00% and 9.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accuray's (ARAY) CyberKnife Gets Support From RayStation TPS

by Zacks Equity Research

Accuray (ARAY) introduces RayStation treatment planning support for CyberKnife Radiotherapy System and other radiation therapy devices.

Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT

by Zacks Equity Research

Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.

Accuray (ARAY) Down 13.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.

New Strong Sell Stocks for April 30th

by Zacks Equity Research

ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021

Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues

by Zacks Equity Research

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.

Accuray (ARAY) Reports Break-Even Earnings for Q3

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and 2.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic

Sriparna Ghosal headshot

Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar

by Sriparna Ghosal

Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.

Accuray (ARAY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Accuray (ARAY) registers growth in Service revenues during fiscal Q2.

Accuray (ARAY) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 600.00% and 4.96%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Releases Encouraging Breast Cancer Study Results

by Zacks Equity Research

Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.

Accuray (ARAY) Gets 510(k) Nod for ClearRT in TomoTherapy

by Zacks Equity Research

Accuray (ARAY) new innovative imaging solution is designed to provide cost effective and exceptional diagnostic quality image.

Accuray (ARAY) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Accuray (ARAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.

Accuray (ARAY) Is Up 1.82% in One Week: What You Should Know

by Zacks Equity Research

Does Accuray (ARAY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Accuray (ARAY) Inks Cancer Treatment Technology Delivery Deal

by Zacks Equity Research

Accuray's (ARAY) new deal with DHL Supply Chain will help in the delivery of advanced cancer treatment technology.

Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates

by Zacks Equity Research

Accuray (ARAY) registered growth in Service revenues in Q1.

Accuray (ARAY) Reports Break-Even Earnings for Q1

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 100.00% and 10.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?